IL-17 inhibitors like secukinumab, ixekizumab and brodalumab have shown high levels of efficacy, with over 80% of patients achieving 75% reduction in Psoriasis Area and Severity Index (PASI) scores in trials (36). This evidence concerns the gene IL17A and psoriasis.